Clinical Trials
34 trialsAdjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy
Rutgers, The State University of New Jersey
A Phase II Study to Evaluate GFH375 in Patients With KRAS G12D Mutant Metastatic Pancreatic Cancer
Genfleet Therapeutics (Shanghai) Inc.
A Phase II Study of Adjuvant Immunotherapy Targeting KRAS G12D, KRAS G12V, or TP53 R175H for Participants With Advanced Gastrointestinal Malignancies
National Institutes of Health Clinical Center (CC)
PRIMUS006
University of Glasgow
XACT-PANC-2
University of Iowa
QUILT-3.088: NANT Pancreatic Cancer Vaccine
ImmunityBio, Inc.
OVERPASS
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
A Study to See Whether a Nutritional Supplement is Beneficial for Patients With Pancreatic Cancer
University of Alberta
CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X)
Case Comprehensive Cancer Center
Evaluate Efficacy of Devimistat in Combination With mFFX in 2nd Line Patients With Metastatic Pancreatic Cancer
Cornerstone Pharmaceuticals
Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of Patients With Locally-advanced, Unresectable, or Metastatic Pancreatic Ductal Adenocarcinoma
OHSU Knight Cancer Institute
The Effect of Cannabis in Pancreatic Cancer
University of Copenhagen
Pemigatinib in Subjects With Adenosquamous Carcinoma of the Pancreas
HonorHealth Research Institute
CKPancreas
Centre Francois Baclesse, Luxembourg
Adavosertib and Gemcitabine in Advanced Pancreatic
Dana-Farber Cancer Institute
HIPEC as Neoadjuvant Treatment for Resectable Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Pancreatic Cancer
Fuda Cancer Hospital, Guangzhou
Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer
New York Presbyterian Brooklyn Methodist Hospital
A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection
University of Colorado, Denver
Genistein in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery
Jonsson Comprehensive Cancer Center
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
University of Cincinnati
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
Indiana University
Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1
University of Hawaii
Panc-Durval+RT
University of Maryland, Baltimore
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
PanCAN
Georgetown University
Study of Mitomycin-C in Patients With Advanced or Recurrent Pancreatic Cancer With Mutated BRCA2 Gene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Safety Study of Adjuvant Gemcitabine Started One Week After Laparoscopic Distal Pancreatectomy for Adenocarcinoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Gemcitabine Hydrochloride With or Without Bevacizumab in Treating Patients Who Are Undergoing Surgery for Pancreatic Cancer
National Cancer Institute (NCI)
Cvac as Maintenance Treatment Patients With Resected Stage I or Stage II Adenocarcinoma (Cancer) of the Pancreas
Prima BioMed Ltd
PMABIIS
University of Massachusetts, Worcester
Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or Recurrent Cancer of the Pancreas
University of Alabama at Birmingham
Comparing Endoscopic Based Stent Strategy Versus Bypass Surgery in Non-resectable Periampullary Cancer
Karolinska Institutet